Olli Kallioniemi

Professor of Molecular Precision Medicine at the Karolinska Institutet and Director of the Science for Life Laboratory (2015-), a national infrastructure for life sciences in Sweden.

Professor Kallioniemi received his M.D. (1984), Ph.D. (1988) and certification in laboratory medicine (1990) at the University of Tampere in Finland. He undertook a postdoc at UC San Francisco in 1990-1992 and was appointed faculty at the National Human Genome Research Institute, at the NIH (1995-2002). He founded and developed the Medical Biotechnology group at Turku, Finland with VTT and Univ. Turku (2002-2008) and served as an Academy Professor in 2006-2008). Prof. Kallioniemi was the Founding Director of FIMM – the Institute for Molecular Medicine Finland and professor at the University of Helsinki since 2008. FIMM is an international molecular medicine research institution at the University of Helsinki formed in partnership with the European Molecular Biology Laboratory (EMBL). Olli Kallioniemi is an author of 349 publications, a member of the editorial board of four journals and has been an invited lecturer in over 100 meetings during the past 10 years.

He has supervised 22 doctoral theses and mentored 27 postdocs. He is an inventor in 20 issued patents and several pending applications, with a focus on technologies for molecular diagnostics and precision medicine, such as FISH, Comparative Genomic Hybridization, tissue microarrays, cell-based microarrays, and bioinformatic methods as well as biomarkers of drug response. Olli Kallioniemi’s current research is focussing on individualized systems medicine to promote precision care of cancer patients. Olli is a founder of bioinformatics startup (Medisapiens) as well as engaged in a number of major industrial collaborations involving e.g. Pfizer, Bayer, Roche, and Labcyte.